Welcome to our dedicated page for Kenwin Shops news (Ticker: KNWN), a resource for investors and traders seeking the latest updates and insights on Kenwin Shops stock.
Know Labs, Inc. (KNWN) generates news that centers on its radio frequency dielectric spectroscopy (RFDS) platform, non-invasive diagnostic ambitions, intellectual property portfolio, and stock market developments. As a public company trading under the KNWN symbol in the over-the-counter market, its announcements often combine technology updates with information relevant to investors and partners.
Readers following KNWN news will find updates on Know Labs’ progress toward commercializing its RFDS-based platform, including its first expected application in a non-invasive glucose monitoring device that is intended to provide real-time blood glucose information, subject to U.S. Food and Drug Administration clearance or approval. The company also issues news about its Know Labs Technology Licensing (KTL) division, which focuses on licensing its RFDS technology to corporations, universities, and research institutions.
Another recurring theme in Know Labs’ news flow is its intellectual property. The company reports on the size and composition of its patent and trade secret portfolios and highlights third-party analyses of its IP position in certain medical diagnostics and industrial process control categories. Announcements may also describe new licensing frameworks, client engagement processes, and tools such as the e-RFDS™ digital watermark for authentication and counterfeit protection.
From a capital markets perspective, Know Labs issues releases on listing status, reverse stock splits, appeals of exchange delisting proceedings, and transitions between NYSE American and over-the-counter trading venues, including approval to quote on the OTCQB Venture Market. For investors, technologists, and potential licensees, this news page offers a consolidated view of the company’s disclosures on technology development, IP strategy, licensing initiatives, financial reporting dates, and trading status under the KNWN ticker.
Know Labs, Inc. (OTCQB: KNWN) announced the granting of three new patents for its Bio-RFIDTM platform, supporting its medical diagnostic focus and potential non-medical applications. These patents enhance the company's intellectual property in radio frequency and microwave spectroscopy. The unique antenna configurations improve Bio-RFID's detection capabilities for various analytes. The company aims to leverage this technology for non-invasive glucose monitoring and other medical applications, positioning itself strongly in the diagnostics market.
Know Labs, Inc. (OTCQB: KNWN) has secured a significant patent for its Bio-RFID technology, increasing its total to 23 issued and 34 pending patents. This foundational patent enhances the company's competitive edge in non-invasive medical diagnostics, particularly in glucose monitoring. The patent, related to the arrangement of antennas in the Bio-RFID system, is critical for developing medical devices. Know Labs aims to revolutionize the diagnostics industry and plans to advance towards FDA approval for its glucose monitor, marking a potential turning point.
Know Labs, Inc. (OTCQB: KNWN) has secured a new patent for its Bio-RFID™ technology, increasing its total patent portfolio to 57 issued and pending patents. This latest patent focuses on enhancing the accuracy of non-invasive glucose monitoring, a crucial step in advancing their product for FDA clinical trials. CEO Phil Bosua emphasized the significance of controlled frequency capture for precise measurements. The company has also reported successful results from an independent pre-clinical study validating the Bio-RFID technology, underscoring its potential for disease prevention and diagnostics.
Know Labs, Inc. (OTCQB: KNWN) has announced successful results from an independent pre-clinical study validating its Bio-RFID™ platform technology. This technology aims to provide the world’s first non-invasive continuous glucose monitor, potentially benefiting 1.5 billion people with diabetes or pre-diabetes. The upcoming phase will involve clinical human studies to measure blood glucose levels non-invasively, which will be included for FDA pre-submission. The results will be submitted for publication in a peer-reviewed journal, marking a significant milestone in Know Labs’ regulatory strategy.
Know Labs, a leader in non-invasive medical diagnostics, announced findings from Texas Biomedical Research Institute showcasing the Particle bulb's efficacy in inactivating SARS-CoV-2, the virus responsible for COVID-19. The tests revealed a 95% viral reduction after 5 hours, 99% after 6 hours, and 99.9% after 8 hours. Unlike UV-C light, the Particle bulb utilizes a Gentle UV method, making it safe for use around people. The results highlight the device's potential in combating viruses and household germs.
Know Labs, Inc. (OTCQB: KNWN) has successfully closed $14.2 million in financing, primarily from existing investors. This funding is essential for advancing the development of its proprietary technology aimed at non-invasive blood glucose monitoring and supports the company's plans to up list on a major exchange like NASDAQ or NYSE. The financing provides adequate capital to ensure product development is on track and highlights the company’s commitment to FDA approval for its innovative technology.
Know Labs, Inc. (OTCQB: KNWN) announced its intention to uplist to a major national exchange, either NASDAQ or the NYSE, initiating the listing application process. This move aims to enhance visibility, attract institutional investors, and increase liquidity for its common shares. The company highlighted significant achievements, including receiving a foundational patent and closing a $5.7 million financing to support its glucose monitoring technology. Additionally, its subsidiary, Particle, Inc., is developing a hybrid disinfecting light bulb targeting common germs and viruses, including SARS-CoV-2.
Know Labs, Inc. (OTCQB:KNWN), a leader in non-invasive diagnostics, announced its participation in the LD 500 investor conference on September 1, 2020. Chairman Ron Erickson will present at 1:00 PM PST. This conference, from September 1 to 4, marks a significant shift as it becomes accessible to all due to COVID-19. The company’s first product, the non-invasive UBAND Continuous Glucose Monitor, utilizes innovative Bio-RFID technology, allowing for efficient diagnostics. Attendees can learn more through the provided registration link.